Literature DB >> 15824184

NO excess risk of breast cancer among female users of systemic glucocorticoids.

Henrik Toft Sørensen1, Lene Mellemkjaer, Mette Vinther Skriver, Timothy L Lash, Jørgen H Olsen, John A Baron.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15824184     DOI： 10.1158/1055-9965.EPI-04-0488

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN： 1055-9965            Impact factor:   4.254


× No keyword cloud information.
  6 in total

1.  Glucocorticoid prescriptions and breast cancer recurrence: a Danish nationwide prospective cohort study.

Authors:  L W Lietzen; T Ahern; P Christiansen; A B Jensen; H T Sørensen; T L Lash; D P Cronin-Fenton
Journal:  Ann Oncol       Date:  2014-09-15       Impact factor: 32.976

2.  Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study.

Authors:  Gitte Vrelits Sørensen; Deirdre P Cronin-Fenton; Henrik Toft Sørensen; Sinna Pilgaard Ulrichsen; Lars Pedersen; Timothy L Lash
Journal:  Breast Cancer Res       Date:  2012-02-03       Impact factor: 6.466

3.  Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark.

Authors:  Cynthia de Luise; Stephan F Lanes; Jacob Jacobsen; Lars Pedersen; Henrik T Sørensen
Journal:  Eur J Epidemiol       Date:  2007-03-07       Impact factor: 12.434

4.  Conisation as a marker of persistent human papilloma virus infection and risk of breast cancer.

Authors:  Mette Søgaard; Dora K Farkas; Anne G Ording; Henrik T Sørensen; Deirdre P Cronin-Fenton
Journal:  Br J Cancer       Date:  2016-06-02       Impact factor: 7.640

5.  Glucocorticoids and breast cancer risk.

Authors:  Kelly A Hirko; A Heather Eliassen
Journal:  BMC Med       Date:  2021-08-02       Impact factor: 8.775

6.  Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women.

Authors:  Laure Dossus; Agnès Fournier; Manon Cairat; Marie Al Rahmoun; Marc J Gunter; Pierre-Etienne Heudel; Gianluca Severi
Journal:  BMC Med       Date:  2021-08-02       Impact factor: 8.775
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.